The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

An organic compound represented by the following general formula [1] is excellent in thermal stability. ##STR00001##
In the general formula [1], R.sub.1 to R.sub.12 are each independently selected from the group consisting of a hydrogen atom and a substituent. Symbol A is selected from the group consisting of a divalent residue of naphthalene, phenanthrene, fluorene, benzofluorene, dibenzofluorene or spirofluorene, and a heteroarylene group having 4 to 12 carbon atoms. Symbol B is selected from the group consisting of an arylene group having 6 to 25 carbon atoms and a heteroarylene group having 4 to 12 carbon atoms. Symbol n is an integer of 0 to 3.

An organic compound represented by the following general formula [1] is excellent in thermal stability. ##STR00001##
In the general formula [1], R.sub.1 to R.sub.12 are each independently selected from the group consisting of a hydrogen atom and a substituent. Symbol A is selected from the group consisting of a divalent residue of naphthalene, phenanthrene, fluorene, benzofluorene, dibenzofluorene or spirofluorene, and a heteroarylene group having 4 to 12 carbon atoms. Symbol B is selected from the group consisting of an arylene group having 6 to 25 carbon atoms and a heteroarylene group having 4 to 12 carbon atoms. Symbol n is an integer of 0 to 3.

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

##STR00001##

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

##STR00001##

A condensed cyclic compound represented by Formula 1 and including 9 to 60 aromatic rings: ##STR00001##
A is a group represented by Formula 10, n is selected from 1, 2, 3, and 4, L is hydrogen, a single bond or a linking group, and when n is 1, p is selected from 1, 2, 3, and 4, and q is selected from 1, 2, 3, and 4, ##STR00002## wherein Formula 10 is the same as described in the specification.

A condensed cyclic compound represented by Formula 1 and including 9 to 60 aromatic rings: ##STR00001##
A is a group represented by Formula 10, n is selected from 1, 2, 3, and 4, L is hydrogen, a single bond or a linking group, and when n is 1, p is selected from 1, 2, 3, and 4, and q is selected from 1, 2, 3, and 4, ##STR00002## wherein Formula 10 is the same as described in the specification.

The present disclosure relates to an organic compound. The structure of the organic compound consists of a structure represented by formula (I) and a structure represented by formula (II); the structure represented by formula (I) is fused with the structure represented by formula (II); and * represents a connection point, in formula (I), capable of being fused with formula (II). When being used to the organic light-emitting layer of an organic electroluminescent device, the organic compound of the present application can effectively improve the device efficiency of the device and prolong the service life of the organic electroluminescent device.

##STR00001##

The present disclosure relates to an organic compound. The structure of the organic compound consists of a structure represented by formula (I) and a structure represented by formula (II); the structure represented by formula (I) is fused with the structure represented by formula (II); and * represents a connection point, in formula (I), capable of being fused with formula (II). When being used to the organic light-emitting layer of an organic electroluminescent device, the organic compound of the present application can effectively improve the device efficiency of the device and prolong the service life of the organic electroluminescent device.

##STR00001##